Drug Profile
Bintrafusp alfa - EMD Serono/Merck
Alternative Names: Anti-PD-L1/TGFbetaRII-fusion-protein; Anti-PDL1/TGFb Trap MSB0011359C; GSK-4045154; M-7824; MSB-0011359CLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator EMD Serono; Merck KGaA
- Developer Bergonie Institute; EMD Serono; EMD Serono Research & Development Institute; GlaxoSmithKline; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); Precigen Inc; University of Hong Kong
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants; Programmed cell death-1 ligand-1 inhibitors; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Biliary cancer; Cervical cancer; Non-small cell lung cancer; Triple negative breast cancer
- Phase II Anal cancer; Nasopharyngeal cancer; Oropharyngeal cancer; Penile cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
- Phase I/II Brain metastases; Colorectal cancer; Pancreatic cancer; Small cell lung cancer
- Phase I Urogenital cancer
- No development reported Breast cancer; HER2 negative breast cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Cervical-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in Japan (IV, Infusion)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Urogenital-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Netherlands (IV, Infusion)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Urogenital-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Spain (IV, Infusion)